Clarivate Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw improved performance with $586M revenue, 1.7% organic subscription growth, and a 41% adjusted EBITDA margin. The Value Creation Plan drove margin expansion, debt reduction, and strong AI innovation, with full-year guidance reaffirmed and continued focus on subscription growth.
-
The company is accelerating its shift to recurring revenue, focusing on high-margin segments and embedding AI across its product suite. Strategic actions include the planned sale of the Life Sciences segment to strengthen the balance sheet and drive growth in core markets. Enhanced sales execution and product innovation are expected to support margin expansion and improved cash flow.
Fiscal Year 2025
-
Delivered on full-year guidance with improved organic growth, recurring revenue, and free cash flow. Initiated LS&H segment sale to focus on A&G and IP, with AI-driven innovation and strong proprietary revenue base supporting positive 2026 outlook.
-
Proprietary data and AI integration are driving innovation, retention, and new revenue streams across all segments. The value creation plan is advancing, with a strong shift to subscription revenue and ongoing efficiency initiatives. Margin and cash flow improvements are expected as the business transitions and invests in AI.
-
Q3 2025 saw flat revenue but improved ACV, renewal rates, and free cash flow, with strong product innovation and AI integration across all segments. Full-year guidance was raised, reflecting slower attrition in disposals and FX tailwinds, while strategic disposals and investments continue to reshape the business.
-
The event detailed a strategic shift to subscription models, significant AI-driven product innovation, and organizational improvements to boost sales and retention. Portfolio rationalization and disciplined capital allocation aim to drive shareholder value, with organic growth and margin expansion expected as disposals conclude.
-
Management expects to complete its strategic review and potential divestiture by year-end, while ongoing business optimization and AI-driven innovation are boosting recurring revenue and product offerings. All segments are targeting market-aligned organic growth, with strong momentum in AI adoption and international expansion.
-
Solid Q2 and H1 2025 results with organic growth across all segments, improved margins, and strong free cash flow. AI-led innovation and a shift to recurring revenue models are driving performance, while strategic reviews and capital allocation actions support future growth.
-
Q1 saw a return to organic revenue growth, improved recurring revenue mix, and higher renewal rates, driven by transformation initiatives and product innovation. Full-year guidance is reaffirmed, with risks from U.S. government funding considered contained within outlook.
Fiscal Year 2024
-
2024 saw improved net loss and strong cash flow, but organic revenue declined due to transactional business contraction. Strategic disposals and a shift to subscription models are expected to boost recurring revenue mix, margins, and predictability in 2025, with organic growth targeted for 2026 and beyond.
-
Q3 revenue declined 2.6% year-over-year, driven by weakness in transactional lines and market headwinds, with net loss impacted by FX and impairment charges. Management is executing a turnaround plan focused on subscription revenue, sales execution, and product innovation, while withdrawing guidance to prioritize transformation.
-
Management is targeting 4-6% organic growth by 2026, driven by investments in product innovation, AI, and a shift toward recurring revenue. Life sciences is expected to be the fastest-growing segment, while margin expansion and balanced capital allocation are planned as growth accelerates.
-
Organic growth is expected at the lower end of guidance due to macro and product challenges in life sciences and IP, but strong A&G performance and new AI-powered products are driving optimism. Capital allocation is shifting toward buybacks and targeted acquisitions, with ongoing investments in technology and product innovation.
-
Q2 revenue declined year-over-year due to divestitures and FX, with a net loss driven by a goodwill impairment. Subscription growth was solid in Academia & Government, while IP and Life Sciences faced macro and product challenges. Full-year guidance is reaffirmed, with a focus on innovation and a balanced capital allocation approach.
-
Management outlined a multi-year plan to accelerate organic growth to 4%-6% by investing in AI, product innovation, and platform modernization. Revenue is shifting toward recurring models, with margin expansion expected as growth improves and major investments peak by 2025.
-
The firm is executing a turnaround across three core segments, targeting 4%-6% organic growth by 2026 through product innovation, AI integration, and a shift to recurring revenue models. Improved financial health enables flexible capital allocation, while proprietary content and real-world data drive competitive advantage.